Funding for this research was provided by:
Received: 6 November 2022
Accepted: 23 December 2022
First Online: 5 January 2023
: This study was IRB approved by Advarra and consent was received from all subjects for participation in this study. The study strictly adhered to the Health Insurance Portability and Accountability Act and all of the tenants of the Declaration of Helsinki. Finally, this study was registered and approved by the Food and Drug Administration under the identification number NCT02732899.
: Consent has been obtained for use of all subject images as a part of the institutional consent for this study.
: Each author’s conflict of interests, both financial and nonfinancial, are enumerated below: Lucas W. Rowe, Robert J. Minturn, Lauren A. Burgett, Peter Bracha have no competing interests to disclose. Raj K. Maturi: Research support through Allergan, Allegro, GlaxoSmithKline, Genentech and Santen. Consulting agreement with Santen.